March Biosciences, Inc is a clinical-stage cell therapy company with a mission to transform patient care in the most challenging hematological malignancies. The lead asset, MB-105, has Phase I efficacy in T-cell lymphoma and leukemia, indications with limited treatment options and an incredibly poor prognosis. We are the first in class in this space and are currently advancing this product towards Phase II studies with registration potential. The company's pipeline is designed to launch a platform to expand on these early successes and more broadly impact other high-challenge cancers
Speaker
